Komori
Daito Pharmaceutical (4577) · PolicyRestated

Enhancing corporate value through transparency, fairness and prompt decision-making

First written in FY2016. 2 of 3 entries say "Restated". Latest entry: FY2018.

3entries
3years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseRestatedFY2016 – FY20182016: 120162017: 120172018: 12018
Same theme, other companies
Enhancing corporate value through transparency, fairness and prompt decision-makingA theme 18 companies write about · 0 as a headwind · 18 as a tailwind

The whole theme swung hardest in 2019: 2 of 9 companies on the "Worse" side.

12 other companies' latest entry also says "Restated".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 18 companies compared. The sentences above are computed from all 18.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for Daito Pharmaceutical yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Enhancing corporate value through transparency, fairness and prompt decision-making | Daito Pharmaceutical Co.,Ltd. (4577) | Komori